CAPR241220C17500
- 0.05
- 0.000.00%
Capricor Therapeutics Newsroom
RFK Jr. Could Prove a Surprise Boon for Stem-cell Stocks With Pivotal Year Ahead
Stem Cells Poised for Success in 2025 as Regulatory Environment Looks More Favorable -- Market Talk
JonesTrading Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $40
12 Health Care Stocks Moving In Thursday's Pre-Market Session
America's Car-Mart Posts Upbeat Sales, Joins Methode Electronics, Verint Systems, Brown-Forman And Other Big Stocks Moving Higher On Thursday
Capricor Therapeutics, Inc. (NASDAQ:CAPR): Are Analysts Optimistic?
Capricor Therapeutics to Present at Upcoming Investor Conferences
Capricor Wins Key EU Designations for the Lead Asset
Capricor Therapeutics Granted Orphan Drug And ATMP Status For Deramiocel By EMA
Express News | Capricor Therapeutics Inc - Expects to Complete Bla Submission by End of 2024
Express News | Capricor Therapeutics Granted Orphan Drug and Atmp Status for Deramiocel by European Medicines Agency
Capricor Therapeutics Analyst Ratings
Capricor Therapeutics Initiated With a Buy at JonesResearch
Express News | Capricor Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $40
Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $25
Capricor Therapeutics | 10-Q: Q3 2024 Earnings Report
Decoding 12 Analyst Evaluations For Capricor Therapeutics
Cantor Fitzgerald Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Raises Target Price to $30
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43
Capricor Therapeutics Price Target Raised to $30 From $25 at Cantor Fitzgerald